Crohn’s Disease | Unmet Need | US/EU | 2021
TNF-alpha inhibitors (e.g., Janssen’s Remicade, AbbVie’s Humira) are the mainstay of biological treatment for moderate to severe Crohn’s disease (CD), while newer biologics (i.e., Takeda’s Entyvio, a CAM inhibitor, and Janssen’s Stelara, an IL-12/23 inhibitor) are mostly used as later-line therapies, following anti-TNF failure. These agents all have safety risks and efficacy limitations, and the launch of biosimilar alternatives has only increased the complexity of CD treatment. Furthermore, significant need remains, especially in the treatment of patients refractory to available therapies and patients with fistulizing disease.
QUESTIONS ANSWERED
- What are the treatment drivers and goals for moderate to severe CD?
- What drug attributes are key influences, which have limited impact, and which are hidden opportunities?
- How do current therapies perform on key treatment drivers and goals for moderate to severe CD?
- What are the prevailing areas of unmet need and opportunity in moderate to severe CD?
- What trade-offs across different clinical attributes and price are acceptable to U.S. and European gastroenterologists for a hypothetical new moderate to severe CD drug?
PRODUCT DESCRIPTION
Provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 60 U.S. and 32 European gastroenterologists fielded in April 2021
Key companies: AbbVie, Janssen, Takeda, UCB, Celltrion Healthcare
Key drugs: Humira and infliximab biosimilar (IV), Remicade, Entyvio, Stelara, Cimzia, adalimumab biosimilar, Remsima SC
